Literature DB >> 2455640

Epidemiological typing of Pseudomonas aeruginosa.

T L Pitt1.   

Abstract

Current knowledge of the typing of Pseudomonas aeruginosa and new methods for characterizing strains are reviewed. A combination of serotyping as a primary screen with pyocin typing for finer discrimination between isolates gives valid epidemiological data, is within the scope of most clinical laboratories and is to be recommended. Phage typing and H typing do provide good discrimination but are not reproducible in practice because a reaction-difference rule has to be applied to phage patterns, and diphasic variation reduces the accuracy of the identification of flagellar antigens. A problem remains with cystic fibrosis isolates, which show considerable heterogeneity in surface properties. For these strains pyocin production typing by the revised method of Govan is indicated. Newer techniques such as isoenzyme profile and DNA probes of the chromosome require independent evaluation and due to their technical difficulty may not be adopted in a routine context for some years to come.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2455640     DOI: 10.1007/bf01963095

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  61 in total

1.  The specificity of agglutination reactions of Pseudomonas aeruginosa with O antisera.

Authors:  T L Pitt; Y J Erdman
Journal:  J Med Microbiol       Date:  1978-02       Impact factor: 2.472

2.  Preparation of agglutinating antisera specific for the flagellar antigens of Pseudomonas aeruginosa.

Authors:  T L Pitt
Journal:  J Med Microbiol       Date:  1981-08       Impact factor: 2.472

3.  Serotypes of Pseudomonas aeruginosa in clinical specimens in relation to antibiotic susceptibility.

Authors:  N J Legakis; M Aliferopoulou; J Papavassiliou; M Papapetropoulou
Journal:  J Clin Microbiol       Date:  1982-09       Impact factor: 5.948

4.  Studies on the pyocins of Pseudomonas aeruginosa: production of contractile and flexuous pyocins in Pseudomonas aeruginosa.

Authors:  J R Govan
Journal:  J Gen Microbiol       Date:  1974-01

5.  Comparison of numerical procedures for grouping pseudomonas bacteriophages according to lytic spectra.

Authors:  T Bergan
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1972

6.  Pyocine typing of Pseudomonas aeruginosa: association between antigenic structure and pyocine type.

Authors:  K Csiszár; B Lányi
Journal:  Acta Microbiol Acad Sci Hung       Date:  1970

7.  Polyagglutinating and non-typable strains of Pseudomonas aeruginosa in cystic fibrosis.

Authors:  T L Pitt; J MacDougall; A R Penketh; E M Cooke
Journal:  J Med Microbiol       Date:  1986-03       Impact factor: 2.472

Review 8.  Composition and structure of lipopolysaccharides from Pseudomonas aeruginosa.

Authors:  S G Wilkinson
Journal:  Rev Infect Dis       Date:  1983 Nov-Dec

9.  Hospital outbreaks caused by Pseudomonas aeruginosa: importance of serogroup O11.

Authors:  J J Farmer; R A Weinstein; C H Zierdt; C D Brokopp
Journal:  J Clin Microbiol       Date:  1982-08       Impact factor: 5.948

10.  Possibility of using purified pyocins for typing Pseudomonas aeruginosa: purification of pyocins and sensitivity of P. aeruginosa in different tests.

Authors:  D Jurado Chacon; A Chueca Sancho; J F Guillen Solvas; B Garcia-Villanova Ruiz; R Galvez Vargas
Journal:  Ann Inst Pasteur Microbiol (1985)       Date:  1986 May-Jun
View more
  30 in total

1.  Pseudomonas aeruginosa: a survey of resistance in 136 hospitals in Spain. The Spanish Pseudomonas aeruginosa Study Group.

Authors:  E Bouza; F Garcia-Garrote; E Cercenado; M Marin; M S Diaz
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

2.  Molecular epidemiological analysis of Pseudomonas aeruginosa strains causing failure of antibiotic therapy in cystic fibrosis patients.

Authors:  E Bingen; E Denamur; B Picard; P Goullet; N Lambert-Zechovsky; P Foucaud; J Navarro; J Elion
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-05       Impact factor: 3.267

3.  Characteristics of Pseudomonas aeruginosa strains causing septicemia in a Spanish hospital 1981-1990.

Authors:  F Vázquez; M C Mendoza; M H Villar; A Vindel; F J Méndez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-08       Impact factor: 3.267

4.  Emergence of resistance to beta-lactam agents in Pseudomonas aeruginosa with group I beta-lactamases in Spain.

Authors:  K Colom; A Fdz-Aranguiz; E Suinaga; R Cisterna
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-11       Impact factor: 3.267

5.  Heterogeneity, persistence, and distribution of Pseudomonas aeruginosa genotypes in cystic fibrosis patients.

Authors:  M Fegan; P Francis; A C Hayward; J A Fuerst
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

6.  Multiresistant serotype O 12 Pseudomonas aeruginosa: evidence for a common strain in Europe.

Authors:  T L Pitt; D M Livermore; D Pitcher; A C Vatopoulos; N J Legakis
Journal:  Epidemiol Infect       Date:  1989-12       Impact factor: 2.451

7.  Lipopolysaccharide profile typing as a technique for comparative typing of gram-negative bacteria.

Authors:  H M Aucken; T L Pitt
Journal:  J Clin Microbiol       Date:  1993-05       Impact factor: 5.948

8.  A major Pseudomonas aeruginosa clone common to patients and aquatic habitats.

Authors:  U Römling; J Wingender; H Müller; B Tümmler
Journal:  Appl Environ Microbiol       Date:  1994-06       Impact factor: 4.792

9.  Discriminatory power of three DNA-based typing techniques for Pseudomonas aeruginosa.

Authors:  H Grundmann; C Schneider; D Hartung; F D Daschner; T L Pitt
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

10.  Genome macrorestriction analysis of diversity and variability of Pseudomonas aeruginosa strains infecting cystic fibrosis patients.

Authors:  M J Struelens; V Schwam; A Deplano; D Baran
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.